Funding for this research was provided by:
University of Melbourne
Article History
Received: 24 June 2022
Accepted: 12 August 2022
First Online: 27 August 2022
Declarations
:
: Dr Kenneth Chen has received reimbursement for participation in advisory boards and delivering lectures from Astellas Pharmaceuticals, Janssen Pharma, Bayer and Astra Zeneca. Dr Louise Kostos has no conflicts of interest to declare. A/Prof Arun Azad has the following disclosures: Consultant — Astellas, Janssen, Novartis, Aculeus Therapeutics Speakers Bureau — Astellas, Janssen, Novartis, Amgen, Ipsen, Bristol Myers Squibb; Merck Serono, Bayer Honoraria — Astellas, Novartis, Sanofi, AstraZeneca, Tolmar, Telix; Merck Serono; Janssen, Bristol Myers Squibb, Ipsen, Bayer, Pfizer, Amgen, Noxopharm, Merck Sharpe Dome, Aculeus TherapeuticsScientific Advisory Board — Astellas, Novartis, Sanofi, AstraZeneca, Tolmar, Pfizer, Telix; Merck Serono; Janssen, Bristol Myers Squibb, Ipsen, Bayer, Merck Sharpe Dome, Amgen, Noxopharm Travel + Accommodation—Astellas, Merck Serono, Amgen, Novartis, Janssen, Tolmar, PfizerResearch Funding —Astellas (investigator), Merck Serono (investigator), Astra Zeneca (investigator), Bristol Myers Squibb (institutional), Astra Zeneca (institutional), Aptevo Therapeutics (institutional), Glaxo Smith Kline (institutional), Pfizer (institutional), MedImmune (institutional), Astellas (institutional), SYNthorx (institutional), Bionomics (institutional), Sanofi Aventis (institutional), Novartis (institutional), Ipsen (institutional), Exelixis (institutional), Merck Sharpe Dome (institutional), Janssen (institutional), Eli Lilly (institutional), Gilead Sciences(institutional), Merck Serono (institutional).